title: Effects of ulinastatin and docetaxel on breast cancer invasion and expression of uPA, uPAR and ERK.
abstract: OBJECTIVE
  To investigate the effects of ulinastatin and docetaxel on invasion of breast cancer cells and expression of uPA, uPAR and ERK, breast cancer MDA-MB-231 and MCF-7 cells.
  
  
  METHODS
  The nude mice were treated with PBS, ulinastatin, docetaxel, and ulinastatin plus docetaxel, respectively. Their effects on 1) cell invasion ability was assayed using Transwell; 2) expression of uPA, uPAR and ERK was detected by real time PCR and Western blot; 3) uPA, uPAR and p-ERK protein level in nude mice was quantified by immunohistochemistry.
  
  
  RESULTS
  1) Treatment with ulinastatin, docetaxel, and ulinastatin plus docetaxel, respectively, significantly inhibited MDA-MB-231 and MCF-7 cell invasion; 2) mRNA and protein levels of uPA, uPAR and ERK1/2 were inhibited by ulinastatin, but enhanced by docetaxel.
  
  
  CONCLUSIONS
  Ulinastatin can enhance the effects of docetaxel on invasion of breast cancer cells. And that uPA, uPAR and p-ERK expression is obviously inhibited by ulinastatin.
authors.affiliation: Department of Breast, Pancreas, and Thyroid Surgery Second Affiliated Hospital of Chongqing Medical University, Yuzhong District, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Luo
authors.forename: Xin
authors.initials: X
authors.lastname: Sun
authors.forename: Feng
authors.initials: F
authors.lastname: Gao
authors.forename: Xiaoliang
authors.initials: X
authors.lastname: Zhao
authors.forename: Biao
authors.initials: B
authors.lastname: Zhong
authors.forename: Hong
authors.initials: H
authors.lastname: Wang
authors.forename: Zhijun
authors.initials: Z
authors.lastname: Sun
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D015153:Blotting, Western; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology*; D045744:Cell Line, Tumor; D000077143:Docetaxel; D004359:Drug Therapy, Combination; D005260:Female; D006023:Glycoproteins / Q000494:pharmacology*; D006801:Humans; D007124:Immunoenzyme Techniques; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D048052:Mitogen-Activated Protein Kinase 3 / Q000235:genetics / Q000378:metabolism*; D009361:Neoplasm Invasiveness; D010766:Phosphorylation / Q000187:drug effects; D012333:RNA, Messenger / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D055293:Receptors, Urokinase Plasminogen Activator / Q000235:genetics / Q000378:metabolism*; D043823:Taxoids / Q000494:pharmacology*; D014361:Trypsin Inhibitors / Q000494:pharmacology; D014568:Urokinase-Type Plasminogen Activator / Q000235:genetics / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D006023:Glycoproteins; D012333:RNA, Messenger; D055293:Receptors, Urokinase Plasminogen Activator; D043823:Taxoids; D014361:Trypsin Inhibitors; D000077143:Docetaxel; D048052:Mitogen-Activated Protein Kinase 3; D014568:Urokinase-Type Plasminogen Activator; C028665:urinastatin